Literature DB >> 9013279

In vitro chemosensitivity of human pancreatic cancer cell lines.

Y Sawabe1, H Yamagishi, N Yamaguchi, Y Yamamura, T Oka.   

Abstract

CONCLUSION: These results show that eight pancreatic cancer cell lines are broadly sensitive to CDDP, and that chemotherapy for pancreatic cancer may improve the prognosis by more effective drug delivery to cancer cells.
BACKGROUND: Chemotherapy for pancreatic cancer does not satisfactorily improve prognosis. The efficacy of chemotherapy depends on choosing sensitive anticancer drugs.
METHODS: The in vitro chemosensitivity of eight human pancreatic cancer cell lines was investigated. Growth inhibition was measured by 3H-thymidine incorporation assays for doxorubicin hydrochloride (ADM), mitomycin C (MMC), cisplatin (CDDP), and etoposide (VP-16), and by Alamar Blue assay for (AB assay) 5-fluorouracil (5-FU). The cells were exposed to ADM, MMC, CDDP, and VP-16 for 2 h, and 5-FU for 72 h. From the dose-response curves, the 50% growth inhibition (IC50) level for each drug was estimated.
RESULTS: The IC50 after 2 h of exposure of each of the eight kinds of cell lines to each anticancer drug ranged from 0.12-8.2 micrograms/mL for ADM, 0.066-25 micrograms/mL for MMC, 0.57-7 micrograms/mL for CDDP, 0.68-300 micrograms/mL for VP-16. IC50 after 72 h of exposure to 5-FU ranged from 1.8-23 micrograms/mL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9013279     DOI: 10.1007/BF02803767

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  26 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  Chemosensitivity test for carcinoma of digestive organs.

Authors:  Y Maehara; S Kohnoe; K Sugimachi
Journal:  Semin Surg Oncol       Date:  1990

3.  A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay.

Authors:  S A Ahmed; R M Gogal; J E Walsh
Journal:  J Immunol Methods       Date:  1994-04-15       Impact factor: 2.303

Review 4.  Overview of chemotherapy for pancreatic cancer.

Authors:  S G Arbuck
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

5.  Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer.

Authors:  A Zerbi; V Fossati; D Parolini; M Carlucci; G Balzano; G Bordogna; C Staudacher; V Di Carlo
Journal:  Cancer       Date:  1994-06-15       Impact factor: 6.860

6.  In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve.

Authors:  Y Mitsuhashi; M Inaba; Y Sugiyama; T Kobayashi
Journal:  Cancer       Date:  1992-11-15       Impact factor: 6.860

7.  [Study of in vitro cancer sensitivity of anticancer drugs by SDI (succinate dehydrogenase inhibition test)].

Authors:  Y Kikuchi
Journal:  Gan To Kagaku Ryoho       Date:  1994-12

8.  A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.

Authors:  M Büchler; H Friess; K H Schultheiss; C Gebhardt; R Kübel; K H Muhrer; M Winkelmann; T Wagener; R Klapdor; M Kaul
Journal:  Cancer       Date:  1991-10-01       Impact factor: 6.860

9.  Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

Authors:  K R Palmer; M Kerr; G Knowles; A Cull; D C Carter; R C Leonard
Journal:  Br J Surg       Date:  1994-06       Impact factor: 6.939

10.  Effectiveness of chemotherapy for advanced adenocarcinoma of the pancreas in combined modality therapy.

Authors:  H Kato; H Wakasugi; M Yokota; M Furukawa; T Mukuta; Y Yamada; A Funakoshi
Journal:  Intern Med       Date:  1994-03       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.